OR YEHUDA, Israel, Oct. 9, 2015 /PRNewswire/ -- Valtech Cardio,
Ltd., an innovator in the development of surgical and transcatheter
devices for mitral and tricuspid valve repair and replacement,
announces planned activities at the upcoming Transcatheter
Cardiovascular Therapeutics (TCT) Annual Meeting being held
October 11-15, 2015, at the Moscone
Center in San Francisco,
California. A series of presentations and events will center
on the company's Cardioband® Mitral Reconstruction
System, (Cardioband), a proprietary implantable mitral
reconstruction device with a transfemoral, transseptal delivery
system for mitral valve repair, which recently earned CE Mark
approval.
"The recent CE Mark approval of Cardioband represents a
significant milestone for this technology, and, ultimately, for
patients with heart failure. The designation by the European
regulatory body signifies that Cardioband is a safe treatment
option for patients with mitral regurgitation, and recent clinical
trial data demonstrate its efficacy," said Amir Gross, founder and CEO of Valtech Cardio.
"We look forward to demonstrating at the TCT meeting how Cardioband
provides a significant addition to the armamentarium of heart
surgeons to facilitate mitral valve repair in a first-line setting
while preserving the ability to perform future percutaneous or
surgical valve repair and/or replacement."
In a multicenter feasibility trial including over 50 patients,
Cardioband was shown to significantly reduce annular size, with
significant improvement in mitral regurgitation (MR). After 6
months of follow-up, 80% of patients (n = 25) were categorized in
NYHA Class I-II, with significant improvement of quality of life as
measured with the Minnesota Living With Heart Failure Questionnaire
score of 38 to 18 [p<0.05] and had six-minute walk test score of
241 to 326 [p<0.05]). At 12 months' follow-up, 95% of patients
(n=17) had sustained MR </= 2+.
"The Valtech Cardioband is a safe and easy to use device that
helps to reduce functional mitral regurgitation in patients with
heart failure and impaired left ventricular function. Patients can
receive early intervention with the Cardioband, meaning a better
chance of left ventricular remodeling, and, thus, a higher
probability of a successful clinical outcome. Finally, in my
experience, I have found the system is easy to learn due to a
well-structured training," said Alec
Vahanian, M.D., Head of the Department of Cardiology, Bichat
Hospital, Paris, France.
Several sessions and lectures at TCT will highlight Valtech's
technologies, including Cardioband and CardioValve™:
- On Monday, October
12th, Prof. Francesco
Maisano will present "Valtech Cardiovalve: Novel Design
Features and Clinical Updates" at 4:24
pm during the Transcatheter Mitral Valve Replacement:
Devices and Early Experiences session, held from 3:09 pm – 5:10 PM
pm, in room 3014-3018 of Moscone West, 3rd floor
- On Wednesday, October 14th,
during the Transcatheter Mitral Annuloplasty and Ventriculoplasty
session, held from 3:48 pm - 5:30 pm, in room 3014-3018
of Moscone West, 3rd Floor, Prof. Karl-Heinz Kuck, MD, will present, "Cardioband:
Device Description, Latest Data, and Future Directions" at
4:04 pm followed by Prof.
Alec S. Vahanian, who will present
"Cardioband: Case in a Box" at 4:14
pm, and Prof. Paul A.
Grayburn, MD, who will present "Cardioband Mechanism of
Action: Echocardiographic Insights (2-D and 3-D)" at 4:20 pm.
- On Thursday, October 15, in room
104 of Moscone South, Prof. Vahanian will present "Up-to-1-Year
Follow-up Results of the Transcatheter Annuloplasty Ring
Multicentre Trial" during the TCT Award-Winning Oral Abstracts. Dr.
Vahanian is scheduled to speak at 1:00
pm
Cardioband Mitral Reconstruction System
The Cardioband System combines a reconstruction implant, similar
to the surgical annuloplasty devices, with a transfemoral,
transseptal delivery system. The sutureless connection of the
implant to the mitral annulus is achieved using specially designed
anchors. Reshaping of the mitral annulus to eliminate Mitral
Regurgitation (MR) is done under physiological conditions and
echocardiographic guidance for optimal results. Cardioband received
CE Mark approval after clinical trial results demonstrated the
device is a safe and efficacious intervention option for patients
with functional mitral regurgitation (FMR).
About Valtech Cardio, Ltd.
Valtech Cardio, Ltd., founded in 2005, is a privately held
company specializing in the development of devices for mitral and
tricuspid valve repair and replacement. Valtech Cardio has full
in-house development, manufacturing, and clinical research
capabilities, and over 130 patents and patent applications. The
company, comprised of multidisciplinary development teams, works in
close collaboration with world-renowned heart specialists to
provide the best possible therapy for mitral patients. Funded in
part from investments made by HeartWare International, Inc.
(Nasdaq: HTWR) and other private investors, Valtech Cardio, Ltd.,
is headquartered in Or Yehuda, Israel. For more information,
visit the company's website: www.valtechcardio.com.
For additional
Valtech information:
|
Media Contact for
Valtech:
|
Amir
Gross
|
Jessica
Griffith
|
CEO and Founder,
Valtech
Cardio
|
Pascale
Communications, LLC
|
Phone:
+972.3.5335959
|
+1.610.618.0013
|
Email: amir@valtechcardio.com
|
Jessica@pascalecommunications.com
|
Logo - http://photos.prnewswire.com/prnh/20150914/266007LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/valtechs-ce-mark-approved-cardioband-for-transcatheter-mitral-valve-repair-to-be-highlighted-at-the-2015-transcatheter-cardiovascular-therapeutics-annual-meeting-300157292.html
SOURCE Valtech Cardio, Ltd.